Low-Dose Aspirin in in Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatments

The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00683202

Enrollment

374

Registered

2008-05-23

Start date

2001-03-31

Completion date

2006-03-31

Last updated

2008-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extrauterine Pregnancy, Intrauterine Fetal Growth Restriction, Miscarriage Less Than 12 Gestational Weeks, Preeclampsia, Pregnancy

Keywords

Assisted reproduction, Ovarian response, Uteroplacental hemodynamics, Doppler ultrasonography, Implantation rate, Pregnancy rate, Live birth rate

Brief summary

In this study we hypothesized that low-dose aspirin therapy (100 mg daily) improves ovarian responsiveness, uterine haemodynamics and clinical pregnancy rates in unselected subjects undergoing IVF/ICSI when the treatment is started concomitantly with controlled ovarian hyperstimulation.

Detailed description

Low-dose acetylsalicylic acid irreversibly inhibits the cyclo-oxygenase enzyme in platelets, thus preventing the synthesis of thromboxane, which causes vasoconstriction and platelet aggregation. By this mechanism low-dose aspirin may enhance ovarian and uterine blood flow and tissue perfusion and thus improve ovarian responsiveness for gonadotrophins and endometrial receptivity for implantation. Randomized controlled studies and meta-analyses on the low-dose aspirin therapy to improve IVF/ICSI outcome or uterine hemodynamics have revealed conflicting results.

Interventions

DRUGAcetylsalicylic acid

Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection

DRUGPlacebo

Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Inclusion criteria

* age \< 40 years * \< 4 previous ovarian stimulations

Exclusion criteria

* allergy for acetylsalicylic acid

Design outcomes

Primary

Measure	Time frame
Pregnancy rate	Five weeks after embryo transfer

Secondary

Measure	Time frame
Uterine artery and spiral artery pulsatility index values	On the day of embryo transfer

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026